The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Novel Statistical Tools for Monitoring the Safety of Marketed Drugs
Abstract
Robust tools for monitoring the safety of marketed therapeutic products are of paramount importance to public health. In recent years, innovative statistical approaches have been developed to screen large post-marketing safety databases for adverse events (AEs) that occur with disproportionate frequency. These methods, known variously as quantitative signal detection, disproportionality analysis, or safety data mining, facilitate the identification of new safety issues or possible harmful effects of a product. In this article, we describe the statistical concepts behind these methods, as well as their practical application to monitoring the safety of pharmaceutical products using spontaneous AE reports. We also provide examples of how these tools can be used to identify novel drug interactions and demographic risk factors for adverse drug reactions. Challenges, controversies, and frontiers for future research are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Elements of Statistical Learning
Hastie, T., Friedman, J., & Tibshirani, R. (2001) · Springer Series in Statistics · doi:10.1007/978-0-387-21606-5 · Cited by 24,162
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
The environment and disease: association or causation?
Hill, A. B. (2015) · Journal of the Royal Society of Medicine · doi:10.1177/0141076814562718 · Cited by 7,285
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
Evans, S. J. W., Waller, P. C., & Davis, S. (2001) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.677 · Cited by 1,802
Self-citationWacholder, S., Chanock, S., Garcia-Closas, M., El ghormli, L., & Rothman, N. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh075 · Cited by 1,754
A Bayesian neural network method for adverse drug reaction signal generation
Bate, A., Lindquist, M., Edwards, I. R., Olsson, S., Orre, R., Lansner, A., & De Freitas, R. M. (1998) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050466 · Cited by 1,476
van Puijenbroek, E. P., Bate, A., Leufkens, H. G. M., Lindquist, M., Orre, R., & Egberts, A. C. G. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.668 · Cited by 1,372
Dumouchel, W. (1999) · The American Statistician · doi:10.1080/00031305.1999.10474456 · Cited by 878
Self-citationSzarfman, A., Machado, S. G., & O??Neill, R. T. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00001 · Cited by 700
Wysowski, D. K., & Swartz, L. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.12.1363 · Cited by 471
The General Practice Research Database: Role in Pharmacovigilance
Wood, L., & Martinez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 331
Empirical bayes screening for multi-item associations
DuMouchel, W., & Pregibon, D. (2001) · Proceedings of the seventh ACM SIGKDD international conference on Knowledge discovery and data mining · doi:10.1145/502512.502526 · Cited by 266
Self-citationPerspectives on the Use of Data Mining in Pharmacovigilance
Almenoff, J., Tonning, J. M., Gould, A. L., Szarfman, A., Hauben, M., Ouellet-Hellstrom, R., Ball, R., Hornbuckle, K., Walsh, L., Yee, C., et al. (2005) · Drug Safety · doi:10.2165/00002018-200528110-00002 · Cited by 250
Self-citationCausal or Casual?: The Role of Causality Assessment in Pharmacovigilance
Meyboom, R. H. B., Hekster, Y. A., Egberts, A. C. G., Gribnau, F. W. J., & Edwards, I. R. (1997) · Drug Safety · doi:10.2165/00002018-199717060-00004 · Cited by 240
Principles of Signal Detection in Pharmacovigilance
Meyboom, R. H. B., Egberts, A. C. G., Edwards, I. R., Hekster, Y. A., de Koning, F. H. P., & Gribnau, F. W. J. (1997) · Drug Safety · doi:10.2165/00002018-199716060-00002 · Cited by 239
Lindquist, M., St??hl, M., Bate, A., Edwards, I. R., & Meyboom, R. H. B. (2000) · Drug Safety · doi:10.2165/00002018-200023060-00004 · Cited by 230
Norén, G. N., Bate, A., Orre, R., & Edwards, I. R. (2006) · Statistics in Medicine · doi:10.1002/sim.2473 · Cited by 205
Using MedDRA: Implications for Risk Management
Brown, E. G. (2004) · Drug Safety · doi:10.2165/00002018-200427080-00010 · Cited by 204
Accounting for Multiplicities in Assessing Drug Safety: A Three‐Level Hierarchical Mixture Model
Berry, S. M., & Berry, D. A. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00186.x · Cited by 158
Practical pharmacovigilance analysis strategies
Gould, A. L. (2002) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.771 · Cited by 154
van Puijenbroek, E., Diemont, W. L., & van Grootheest, K. (2003) · Drug Safety · doi:10.2165/00002018-200326050-00001 · Cited by 148
Duplicate detection in adverse drug reaction surveillance
Norén, G. N., Orre, R., Bate, A., & Edwards, I. R. (2007) · Data Mining and Knowledge Discovery · doi:10.1007/s10618-006-0052-8 · Cited by 144
Pharmacovigilance in the 21st Century: New Systematic Tools for an Old Problem
Szarfman, A., Tonning, J. M., & Doraiswamy, P. M. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.13.1099.38090 · Cited by 140
Clinical Pharmacokinetics of Allopurinol
Murrell, G. A. C., & Rapeport, G. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611050-00001 · Cited by 131
Almenoff, J. S., DuMouchel, W., Kindman, L. A., Yang, X., & Fram, D. M. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.885 · Cited by 124
Self-citationMoore, T. J. (1998) · JAMA · doi:10.1001/jama.279.19.1571 · Cited by 111
Comparative Performance of Two Quantitative Safety Signalling Methods
Almenoff, J. S., LaCroix, K., Yuen, N., Fram, D. M., & DuMouchel, W. (2006) · Drug Safety · doi:10.2165/00002018-200629100-00005 · Cited by 110
Self-citationAppraisal of the MedDRA Conceptual Structure for Describing and Grouping Adverse Drug Reactions
Cédric Bousquet, B., Lagier, G., Louët, A. L., Beller, C. L., Alain Venot, A., & Jaulent, M. (2005) · Drug Safety · doi:10.2165/00002018-200528010-00002 · Cited by 97
Roux, E., Thiessard, F., Fourrier, A., et al. (2005) · IEEE Transactions on Information Technology in Biomedicine · doi:10.1109/titb.2005.855566a · Cited by 87
Niu, M. T., Erwin, D., & Braun, M. M. (2001) · Vaccine · doi:10.1016/s0264-410x(01)00237-7 · Cited by 85
Spontaneous Reporting in the United States
Kennedy, D. L., Goldman, S. A., & Lillie, R. B. (2000) · Pharmacoepidemiology · doi:10.1002/0470842555.ch10 · Cited by 82
Data Quality Management in Pharmacovigilance
Lindquist, M. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00003 · Cited by 77
Ståhl, M., Lindquist, M., Edwards, I. R., et al. (2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.894 · Cited by 60
Velentgas, P., West, W., Cannuscio, C. C., Watson, D. J., & Walker, A. M. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1192 · Cited by 45
Impact Analysis of Signals Detected from Spontaneous Adverse Drug Reaction Reporting Data
WALLER, P. C., Heeley, E. L., & Moseley, J. (2005) · Drug Safety · doi:10.2165/00002018-200528100-00002 · Cited by 43
Hauben, M., & Reich, L. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004273936 · Cited by 41
Some US Food and Drug Administration perspectives on data mining for pediatric safety Assessment
O’Neill, R. T., & Szarfman, A. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)80071-0 · Cited by 40
Statistical Techniques for Signal Generation
Purcell, P. M., & Barty, S. (2002) · Drug Safety · doi:10.2165/00002018-200225060-00005 · Cited by 36
Why there is a need for pharmacovigilance
Amery, W. K. (1999) · Pharmacoepidemiology and Drug Safety · Cited by 31
Statistics: Analysis and Presentation of Safety Data
Evans, S. J. W., & Nitsch, D. (2005) · doi:10.1002/9780470975053.ch6 · Cited by 30
Self-citationAn Evaluation of Computer-Aided Disproportionality Analysis for Post-Marketing Signal Detection
Lehman, H. P., Chen, J., Gould, A. L., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100233 · Cited by 28
Does Proof of Causality Ever Exist in Pharmacovigilance?
Auriche, M., & Loupi, E. (1993) · Drug Safety · doi:10.2165/00002018-199309030-00008 · Cited by 25
Berlowitz, D. R., Miller, D. R., Oliveria, S. A., Cunningham, F., Gomez‐Caminero, A., & Rothendler, J. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1301 · Cited by 22
Possible strategies for early recognition of potential drug safety problems.
Venulet, J. (1988) · PubMed · Cited by 11
Martin, U., & George, C. F. (2002) · Wiley eBooks · doi:10.1002/0470853093.ch7 · Cited by 3
Cited by
Data Mining of the Public Version of the FDA Adverse Event Reporting System
Sakaeda, T., Tamon, A., Kadoyama, K., & Okuno, Y. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.6048 · Cited by 1,048
Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
Slade, B. A. (2009) · JAMA · doi:10.1001/jama.2009.1201 · Cited by 470
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.50 · Cited by 393
Self-citationHarpaz, R., DuMouchel, W., LePendu, P., Bauer-Mehren, A., Ryan, P., & Shah, N. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.24 · Cited by 333
Self-citationSGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
Fadini, G. P., Bonora, B. M., & Avogaro, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4301-8 · Cited by 242
Metadata
- Authors
- Almenoff, J. S., Pattishall, E. N., Gibbs, T. G., DuMouchel, W., Evans, S. J. W., & Yuen, N.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2007-05-30
- Volume
- 82
- Issue
- 2
- Pages
- 157-166
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1996239270
- Cited by
- 266
- References
- 46
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.